A clinical study of CapeOX+Cetuximab as first line therapy in patents with KRAS/BRAF wild type metastatic colorectal cancer (A pooled analysis of FLEET and FLEET2 study)
Not Applicable
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000031233
- Lead Sponsor
- The nonprofit organization Epidemiological & Clinical Research Organization.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
Not provided
Exclusion Criteria
nane
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Progression free survival